Synta Starts Phase IIb/III Ganetespib Study

The Phase IIb/III trial will evaluate treatment with ganetespib and docetaxel compared with docetaxel alone.

Synta Pharmaceuticals has initiated a Phase IIb/III GALAXY trial of ganetespib in combination with docetaxel in patients with non-small cell lung cancer.

The Phase IIb/III trial will evaluate treatment with ganetespib and docetaxel compared with docetaxel alone, in patients with Stage IIIB or IV non-small cell lung cancer who have completed one prior systemic therapy.

Ganetespib is a potent, synthetic, small-molecule inhibitor of heat-shock protein 90, a molecular chaperone required for the proper folding and activation of many cancer-promoting proteins.

The first stage will assess efficacy as measured by progression-free survival in approximately 240 patients, w